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Free fatty acid receptor-4 (FFAR4), also known as GPR120, has been reported to mediate the beneficial effects of omega-3
polyunsaturated fatty acids (𝜔3-PUFAs) by inducing an anti-inflammatory immune response. Thus, activation of FFAR4 has been
reported to ameliorate chronic low-grade inflammation and insulin resistance accompanying obesity. However, conflicting reports
on the role of FFAR4 inmediating the effects of𝜔3-PUFAs are emerging, suggesting that FFAR4may not be the sole effector. Hence
analyses of the importance of this receptor in relation to other signaling pathways and prominent effects of 𝜔3-PUFAs remain to
be elucidated. In the present study, we used Ffar4 knockouts (KO) and heterozygous (HET) mice fed either low fat, low sucrose
reference diet; high fat, high sucrose 𝜔3-PUFA; or high fat, high sucrose 𝜔6-PUFA diet for 36 weeks. We demonstrate that both
KO and HET mice fed 𝜔3-PUFAs were protected against obesity, hepatic triacylglycerol accumulation, and whole-body insulin
resistance. Moreover, 𝜔3-PUFA fed mice had increased circulating protein levels of the anti-inflammatory adipokine, adiponectin,
decreased fasting insulin levels, and decreased mRNA expression of several proinflammatory molecules within visceral adipose
tissue. In conclusion, we find that FFAR4 signaling is not required for the reported anti-inflammatory and insulin-sensitizing effects
mediated by 𝜔3-PUFAs.
1. Introduction
Obesity is associated with chronic low-grade inflammation
causing inflammation-induced insulin resistance in various
tissues [1, 2]. Overnutrition increases the need for storage
of excess energy, resulting initially in adipocyte hypertro-
phy, later accompanied by hyperplasia, and recruitment of
classically activated, proinflammatory M1 macrophages into
adipose tissue [3, 4]. M1 macrophages secrete proinflam-
matory cytokines, recruiting additional M1 macrophages,
but they also promote resident alternatively activated, anti-
inflammatory M2 macrophages to differentiate towards the
M1 phenotype, thereby propagating a self-amplifying vicious
inflammatory cycle [4–6]. The ability of inflammation to
interfere with insulin signaling was first described for tumor
necrosis factor-𝛼 (TNF𝛼) in 1993 by Hotamisligil et al. [7].
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Upon binding of TNF𝛼, I𝜅B kinase-𝛽 (IKK𝛽) and c-jun N-
terminal amino kinase-1 (JNK1) are activated. These serine
kinases initiate proinflammatory gene transcription through
activation of nuclear factor 𝜅B (NF𝜅B) and activating protein-
1 (AP-1), but they also have the potential to phosphorylate
the insulin receptor substrates 1 and 2 (IRS1 and IRS2),
inhibiting their association with the insulin receptor [1, 8,
9]. Additionally, TNF𝛼-signaling upregulates expression of
Suppressor of Cytokine Signaling (SOCS) protein family
members, which are able to directly bind and antagonize
the insulin receptor [10, 11]. Interleukin-6 (IL-6) mediated
signaling similarly induces expression of proinflammatory
genes and increases the expression of SOCS3 [11, 12]. Besides
decreased glucose uptake into adipocytes, insulin resistance
also leads to enhanced lipolysis augmenting the amount
of circulating nonesterified fatty acids (NEFAs) [13]. This
increases the risk for ectopic lipid accumulation in liver and
muscle, further exacerbating insulin resistance, providing
a link between dysfunctional adipose tissue and fatty liver
[13, 14]. Yet the metabolic impact of adipose tissue inflamma-
tion varies between depots, where inflammation in visceral
adipose tissue exerts a greater negative metabolic impact
than inflammation in subcutaneous adipose tissue [15, 16].
Augmented secretion of cytokines, adipokines, and NEFAs,
especially from visceral adipose tissue, impacts the liver, thus
affecting this key metabolic organ and consequently whole-
body metabolism [6, 15]. Therefore, modalities to decrease
obesity-associated inflammation are of great importance. In
this regard, the discovery that FFAR4 seemed to be the
main receptor mediating the anti-inflammatory and insulin-
sensitizing effects of 𝜔3-polyunsaturated fatty acids (𝜔3-
PUFAs) in adipocytes andmacrophages spurred considerable
interest in this receptor [17]. In recent years, the anti-
inflammatory potential of FFAR4 signaling in other cell types
and tissues, that is, Kupffer cells [18], colonic Caco-2 cells [19],
and hypothalamus [20], has been investigated.
The anti-inflammatory effect of FFAR4 depends on the
scaffold protein, 𝛽-arrestin 2, which upon ligand-binding of
FFAR4 is recruited to the C-terminal, leading to internal-
ization of the complex [17]. The complex is able to inter-
fere with inflammatory signaling pathways, such as TNF𝛼
and toll-like receptor-4 (TLR4) mediated signaling, thereby
decreasing inflammation [17]. This anti-inflammatory effect
of FFAR4 was found to be responsible for the increased
insulin sensitivity in a high fat diet (HFD) fed mouse model
supplemented with 𝜔3-PUFAs [17]. The authors ascribed the
insulin-sensitizing effect of FFAR4 activation to derive from
macrophages [17]. Interestingly, another group foundFFAR4-
deficient HFD fed mice to be more metabolically impaired,
steatotic, and insulin resistant compared to their wild type
(WT) counterparts independent of 𝜔3-PUFA supplementa-
tion, suggesting that FFAR4 per se has an important role in
energy homeostasis [21].
Contradicting the majority of existing literature [17, 21,
22], recent evidence suggests that FFAR4 is dispensable
for the beneficial effects of 𝜔3-PUFAs on HFD-induced
obesity [23], whereas the anti-inflammatory nature of FFAR4
remains largely unchallenged. Here we show that feeding
mice a high dose of𝜔3-PUFAs protects against HFD-induced
Table 1: Diet composition of the three different diets. A detailed
description can be found in supplementary Table S1.
Diet composition
Low fat Fish oil Soy oil
kcal/g 3.82 4.54 4.54
Protein (kcal%) 19 15 15
Fat (kcal%) 17 42 42
𝜔3-PUFA
(% of total fat)
0.82
(4.82)
14.9
(35.48)
2.5
(5.95)
𝜔6-PUFA
(% of total fat)
7.63
(44.88)
1.0
(2.38)
22.75
(54.17)
𝜔6 :𝜔3 ratio 9.31 : 1 0.07 : 1 9.10 : 1
Carbohydrates (kcal%) 64 43 43
Sucrose
(% of total carbohydrate)
13.5
(21,10)
29.5
(60.60)
29.5
(60.60)
obesity, steatosis, insulin resistance, and visceral adipose
tissue inflammation independent of FFAR4 status.
2. Materials and Methods
2.1. Animal Care and Use. The Ffar4 KO mouse strain was
generated by Lexicon Pharmaceuticals Inc. on a mixed back-
ground of 129SVE and C57BL/6J mice. The deleted sequence
of Ffar4 (gene accession NM 181748.2) corresponds to exon
1. Mice were bred at Taconic Laboratories and used under
license (2014-15-2934-01027). All animal experiments were
conducted in accordance with Danish national guidelines
(Amendment #1306 of November 23, 2007) approved by the
Danish Animal Inspectorate, Ministry of Justice.
Male mice were kept as mixed genotypes in cages (𝑛 = 3–
5 per cage) under specific pathogen-free conditions at a 12 h
light/dark cycle, 22-23∘C, and a humidity of 30%. Mice were
scaled once a week from 6 weeks of age and MR-scanned
prior to the insulin tolerance test (ITT) (week 32 after diet
initiation) using EchoMRI 4 in 1 (Texas, USA).
2.2. Diets. Diets were obtained from Ssniff Spezialdia¨ten
GmBH, Germany, with catalog numbers: low fat, low sucrose
reference diet (S8672-E050 EF AIN93G); high fat, high
sucrose fish oil diet/𝜔3-PUFA (S8672-E409 EF D12079B);
and high fat, high sucrose soy oil diet/𝜔6-PUFA (S8672-E408
EF D12079B). Diets were kept at −20∘C when not in use. Diet
composition is shown in Table 1, with a detailed description
in Table S1, in Supplementary Material available online at
http://dx.doi.org/10.1155/2016/1536047. Feed intake (Figures
1(f) and 1(l)) was measured in parallel in single-housed mice
fed the same diets. All other data were derived from group-
housed mice. Mice were given free access to feed and water
and fed fresh experimental diets twice a week from 11 weeks
of age.
2.3. Insulin Tolerance Test (ITT). After 33 weeks on exper-
imental diets mice were feed-deprived for two hours prior
to insulin injections (Actrapid Penfill, Novo Nordisk, Den-
mark). Insulin was diluted in succinylated gelatin (gelofusine,
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Figure 1: Ffar4 HET and KO mice are protected against obesity development on a high fat 𝜔3-PUFA diet. Mice were scaled weekly from
6 weeks of age; experimental diets were initiated when mice were 11 weeks old. ((a)–(f)) Heterozygotes. ((g)–(l)) Knockouts. ((a) and (g))
Weight development, 𝑛 = 6–8. ((b) and (h)) Lean mass from MR scans 32 weeks after diet initiation (43 weeks of age), 𝑛 = 6–8. ((c) and
(i)) Fat mass from MR scans 32 weeks after diet initiation, 𝑛 = 6–8. ((d) and (j)) eWAT weights 36 weeks after diet initiation, 𝑛 = 6–8. ((e)
and (k)) Liver weights 36 weeks after diet initiation, 𝑛 = 6–8. ((f) and (l)) Feed intake measured two times a week in single-housed mice
till 32 weeks after diet initiation, 𝑛 = 5–7. All data are presented as means ± SEM. Both HFDs are compared to the LFD. For (a), (f), (g),
and (l) data were Ln-transformed and 2-way RM ANOVA with Bonferroni correction was performed. All data shown in bar graphs were
Ln-transformed and subjected to 1-way ANOVA with Bonferroni correction. Only statistical significant differences are shown. ∗𝑝 < 0.05,
∗∗𝑝 < 0.01, ∗∗∗𝑝 < 0.001, and ∗∗∗∗𝑝 < 0.0001.
B. Braun Melsungen AG, Germany) to increase accuracy
of insulin delivery. 1 U insulin per kg lean body mass was
injected intraperitoneally (i.p.) after measurements of initial
blood glucose concentrations. Mice were bled from the tail
vein, and blood glucose was measured using the Bayer Con-
tour Glucometer (Bayer Health Care, Germany) at indicated
timepoints (15, 30, 45, 60, 90, and 120minutes after injection).
2.4. Measurement of Insulin and Adiponectin Levels. Plasma
was collected from 5-hour feed-deprived mice by tail vein
bleeding and diluted two times prior to insulin measure-
ments. For adiponectin measurements, plasma was collected
from nonfasted mice by bleeding from the submandibular
vein. For all plasma samples, blood was drawn in EDTA
coated tubes kept on ice and centrifuged at 4∘C for 10 minutes
at 1000×g before storage at −20∘C until further use. Insulin
and adiponectin measurements were carried out using
an electrochemiluminescence assay (Mesoscale Diagnostics,
USA) following the manufacturer’s instructions.
2.5. RNA Extraction and Quantitative RT-PCR. Liver and
epididymal white adipose tissue (eWAT) were homogenized
in TRIreagent (Sigma-Aldrich) using the Precellys homog-
enizer (Bertin Technologies). Chloroform (Sigma-Aldrich)
was added for phase-separation, and RNA was precipitated
by addition of isopropanol (Sigma-Aldrich) and washed
with 75% ethanol (CCS Healthcare) before resuspension in
autoclaved Milli-Q water. 1 𝜇g of total RNA was used for
reverse transcription following manufacturer’s instructions
(ThermoFisher K1621). Samples were diluted in Milli-Q
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Table 2: Primer sequences and annealing temperatures. Primer
sequences and annealing temperature are depicted for relevant
primer pairs.
Primers Primer (forward, reverse) Annealingtemp.
Acox1 5
󸀠GGGTCATGGAACTCATCTTCGA 58∘C
5󸀠GAATGAACTCTTGGGTCTTGGG
Cd68 5
󸀠CTTCCCACAGGCAGCACAG 61∘C
5󸀠AATGATGAGAGGCAGCAAGAGG
Fas 5
󸀠ATTGGTGGTGTGGACATGGTC 61∘C
5󸀠CCCAGCCTTCCATCTCCTG
Il-6 5
󸀠CTCTGCAAGAGACTTCCATCCAGT 60∘C
5󸀠GAAGTGGTATAGACAGGTCTGTTGG
Irs2 5
󸀠TCTGCCAGCACCTATGCAA 60∘C
5󸀠GCTTCACTCTTTCACGACTGTG
Mcad 5
󸀠AGTATGCCCTGGATAGGAAGACAT 60∘C
5󸀠CTTGGTGCTCCACTAGCAGCT
Mcp-1 5
󸀠GTGTTGGCTCAGCCAGATGC 62∘C
5󸀠GCTTGGTGACAAAAACTACAGC
Nrf-1 5
󸀠CAGCACCTTTGGAGAATGTG 55∘C
5󸀠CCTGGGTCATTTTGTCCACA
Ppar𝛾2 5
󸀠ACAGCAAATCTCTGTTTTATGC 60∘C
5󸀠TGCTGGAGAAATCAACTGTGG
Scd1 5
󸀠ACACCTGCCTCTTCGGGATT 61∘C
5󸀠TGATGCCCAGAGCGCTG
Socs3 5
󸀠GCCTTTCAGTGCAGAGTAGTG 63∘C
5󸀠AAGAGCAGGCGAGTGTAGAG
Tbp 5
󸀠ACCCTTCACCAATGACTCCTATG 60∘C
5󸀠ATGATGACTGCAGCAAATCGC
Tnf𝛼 5
󸀠CCCTCACACTCAGATCATCTTCT 63∘C
5󸀠GCTACGACGTGGGCTACAG
water and 4 𝜇L of the cDNA solution was added to a 96-
well plate prior to addition of a mix consisting of 4.8 𝜇L
autoclaved Milli-Q, 0.6 𝜇L forward primer (Tag Copenhagen
A/S), 0.6 𝜇L reverse primer (Tag Copenhagen A/S), and 10 𝜇L
SYBR Green containing ROX as reference dye (Bioline). RT-
PCR was carried out on the Stratagene Mx3000P qPCR
system, where samples were denatured by heating at 95∘C
for 5 minutes followed by 40 cycles of melting at 95∘C for
15 seconds, annealing at differing temperatures as noted
in Table 2 for 15 seconds, and elongation at 72∘C for 20
seconds. Gene expression was normalized to that of Tata-
binding protein (Tbp) mRNA. Primer sequences are given in
Table 2.
2.6. Western Blot Analyses. Protein lysates were prepared
from approximately 10mg of liver tissue using standard
protocols [24]. Western blot analyses were performed as pre-
viously described [24] and protein abundance was detected
by immunoblotting using the following antibody: NF𝜅B p65
(Santa Cruz #sc-109). Protein concentrationwasmeasured by
BCA (#23223 and #23224,Thermo Scientific, USA) according
to the manufacturer’s instructions. Loading consistencies
were verified by Ponceau staining.
2.7. Thin-Layer Chromatography. Triacylglycerol (TAG) was
measured by thin-layer chromatography (TLC) using 7.5mg
liver sample. Lipids were extracted in chloroform-methanol
(2 : 1) using the method of Folch et al. [25] and dissolved
in chloroform as previously described [26]. Lipids were
separated on silica-gel coated plates using two different sepa-
rate mobile phases consisting of chloroform-methanol-acetic
acid-water (50 : 50 : 5 : 5) followed by petroleum ether-diethyl
ether-acetic acid (120 : 25 : 1.5). Butylated hydroxytoluene
(50mg/L) was added to both of the mobile phases. The lipids
were developed by a 10% copper sulfate pentahydrate and
8% phosphoric acid solution at 120∘C for 15min. Lipids were
visualized on a Typhoon FLA 7000 IP fluorescent scanner
and analyzed according to weight using ImageQuant TL (GE
Healthcare Life Sciences, Little Chalfont, United Kingdom).
TAG was identified with a specific glyceryl tripalmitate
(#T5888, Sigma-Aldrich).
2.8. Statistics. All statistical analyses were conducted using
GraphPad Prism version 6 software (GraphPad Software, San
Diego, USA). Data are presented as mean ± standard error of
the mean (SEM).
Due to small and variable sample sizes data could not
be assumed to follow a Gaussian distribution and were
consequently lognormal- (Ln-) transformed prior to any test
except for the ITT where data were normalized to initial
blood glucose (Figures 2(a) and 2(d)). Unless otherwise noted
2-way repeated measures (RM) ANOVA with Bonferroni
post hoc multiple comparison test was conducted for all
time-dependent analyses, that is, weight development, ITT,
and feed intake. For comparison between genotypes 2-
way ANOVA with Bonferroni post hoc multiple comparison
test was conducted. All other data were analyzed by 1-way
ANOVA with Bonferroni post hoc multiple comparison test.
Both HFD groups (𝜔3-PUFA and 𝜔6-PUFA) were compared
to the LFD group. Data were considered statistically signif-
icant with 𝑝 < 0.05 and the different levels of significance
were set to be ∗𝑝 < 0.05, ∗∗𝑝 < 0.01, ∗∗∗𝑝 < 0.001, and
∗∗∗∗𝑝 < 0.0001. Only statistically significant differences are
shown on graphs.
3. Results
FFAR4 is currently believed to be the key receptor for the
polyunsaturated long chain fatty acids, eicosapentaenoic acid
(EPA), and docosahexaenoic acid (DHA) [17], mediating the
beneficial effects of fish oil. Yet, reports challenging this view
are emerging, suggesting that FFAR4 might not serve as the
sole effector of the health beneficial effects of 𝜔3-PUFAs [23],
indicating that fish oil acts through multiple pathways to
exert its beneficial effects on health. We examined if fish oil
on a HFD background would exert a favorable metabolic
effect independent of FFAR4. To address this, we acquired
Ffar4 HET and Ffar4 KO mice from Taconic Laboratories,
Denmark. Importantly, the levels ofFfar4mRNAwere similar
in WT and HET mice, showing that the expression of Ffar4
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Figure 2: Ffar4HET and KOmice are protected against insulin resistance on a high fat𝜔3-PUFA diet. Insulin tolerance tests were performed
at week 33 after diet initiation in 2-hour food-deprived mice. An insulin bolus of 1 U/kg lean mass was injected i.p. ((a)–(c)) Heterozygotes.
((d)–(f)) Knockouts. ((a) and (d)) ITT, 𝑛 = 4–8; ((b) and (e)) 5-hour fasting insulin levels 32 weeks after diet initiation, 𝑛 = 6–8. ((c) and (f))
Plasma adiponectin levels 36weeks after diet initiation, 𝑛 = 4–7. All data are presented asmeans± SEM. BothHFDs have been compared to the
LFD. For (a) and (d), 2-way RM ANOVA with Bonferroni correction was performed. All bar graph data were Ln-transformed and subjected
to 1-way ANOVA with Bonferroni correction. Only statistical significant differences are shown. ∗𝑝 < 0.05, ∗∗𝑝 < 0.01, and ∗∗∗𝑝 < 0.001.
mRNA was not gene dose dependent. No Ffar4 mRNA was
detected in KO mice (Figure S1).
We fed mice an isocaloric high fat, high sucrose diet rich
in either 𝜔3-PUFAs or 𝜔6-PUFAs using fish oil or soy oil,
respectively, as fat sources and compared the results to a low
fat diet (LFD) reference group. Diet composition is shown in
Table 1; a detailed fatty acid composition is given in Table S1.
3.1. The Antiobesogenic Effect of 𝜔3-PUFAs Is Independent
of FFAR4. 𝜔3-PUFAs protected mice against weight gain
irrespective of FFAR4 status for the first 28 weeks of HFD
feeding. At this time, HET mice, but not KO mice, tended to
gain more weight than their LFD fed counterparts (Figures
1(a) and 1(g)). The weight gain protection mediated by 𝜔3-
PUFAs is in sharp contrast to the obesogenic potential of 𝜔6-
PUFAs. Thus, mice, fed the latter, gained substantially more
weight than LFD reference mice (Figures 1(a) and 1(g)). As
evidenced by MR scans, weight gain was not confounded
by increased lean mass (Figures 1(b) and 1(h)) but rather
restricted to increased fat mass (Figures 1(c) and 1(i)), which
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was further supported by increased tissue weights of liver
and eWAT (Figures 1(d)-1(e) and 1(j)-1(k)). Since FFAR4 has
been shown to be implicated in fat preference [27], an effect
on feed intake could be suspected. However, there was no
difference in feed intake between genotypes (2-way ANOVA
𝑝 = 0.9486) nor fat sources (Figures 1(f) and 1(l)).
3.2. FFAR4 Status Does Not Affect Insulin Sensitivity. The
lean phenotype promoted by 𝜔3-PUFAs is generally asso-
ciated with increased insulin sensitivity [28]. However, in
contrast to WT mice, Ffar4 KO mice have been shown to
display attenuated insulin sensitivity upon chow [17] and
HFD [21] feeding. We therefore asked if Ffar4 KO mice in
the current study would develop insulin resistance in the
absence of obesity. After 33 weeks on experimental diets,
mice were subjected to an insulin tolerance test. Independent
of genotypes (AUC, 2-way ANOVA, multiple comparison
𝑝 > 0.9999 for all diets), 𝜔3-PUFA fed mice remained
equally insulin sensitive as LFD reference mice (Figures 2(a)
and 2(d)). In contrast, both HET and KO mice displayed
decreased insulin sensitivity (2-way ANOVARM,main effect
𝑝 = 0.0325 and 0.0324, resp.) and increased fasting plasma
insulin concentration when fed𝜔6-PUFAs (Figures 2(a)-2(b)
and 2(d)-2(e)). The protection against insulin resistance in
𝜔3-PUFA fed mice was independent of FFAR4 status and
correlated with increased levels of the anti-inflammatory,
insulin-sensitizing adipokine, adiponectin [29] (Figures 2(c)
and 2(f)), suggesting a potential mechanism for the observed
protection against insulin resistance.
3.3. 𝜔3-PUFA Fed Mice Are Less Steatotic than 𝜔6-PUFA Fed
Counterparts. To disentangle the insulin-sensitizing, FFAR4
independent effects of 𝜔3-PUFAs, we investigated hepatic
expressions of lipogenic enzymes. Notably, expression of
Stearoyl coenzyme A desaturase-1 (Scd1), encoding an enzyme
required for diet-induced hepatic insulin resistance [30], was
substantially downregulated in 𝜔3-PUFA fed mice compared
to LFD reference mice (Figures 3(a) and 3(g)). Similarly,
expression of fatty acid synthase (Fas) was significantly
decreased in 𝜔3-PUFA fed mice (Figures 3(b) and 3(h))
with a concomitant increased expression of genes involved in
fatty acid oxidation, acyl-CoA oxidase 1 (Acox1) andmedium-
chain acyl-CoA dehydrogenase (Mcad) (Figures 3(c)-3(d),
3(i)-3(j)). This suggests that hepatic de novo lipogenesis was
diminished by 𝜔3-PUFA feeding, regardless of FFAR4 status.
Moreover, expression of the adipogenic marker, peroxisome
proliferator-activated receptor-𝛾2 (Ppar𝛾2), was significantly
increased in 𝜔6-PUFA fed mice compared to LFD reference
mice (Figures 3(e) and 3(k)), possibly reflecting increased fat
storage capacity [31]. In keepingwith this notion,we observed
increased levels of hepatic TAG accumulation (Figures 3(f)
and 3(l)). In line with the observed decreased de novo
lipogenesis, improved hepatic insulin resistance, and reduced
TAG accumulation in 𝜔3 compared with 𝜔6-PUFA fed mice,
hepatic Il-6 expression as well as the protein level of the
proinflammatory nuclear factor, NF𝜅B, was diminished in
𝜔3-PUFA fed mice. Further, expressions of insulin receptor
substrate 2 (Irs2) and NF-E2-related factor 1 (Nrf1) were lower
in𝜔6-PUFA fedmice concurrent with augmented expression
of macrophage chemoattractant protein-1 (MCP-1) (Figures
4(a)–4(j)). Again, no differences between genotypes on either
diet were observed suggesting an independency of FFAR4 in
both the protection and progression of hepatic steatosis.
3.4. 𝜔3-PUFA Fed Mice Show Signs of Decreased Inflam-
mation in the Visceral Adipose Tissue. Immunometabolism,
hallmarked by tissue cross talk, has attracted considerable
attention over the past decade. Adipose tissue harbors mul-
tiple immune cells [32] while adipocytes themselves have
substantial immunomodulatory capacity [6]. FFAR4 has
been shown to promote its positive insulin-sensitizing effect
by inhibitingmacrophage-mediated inflammation in adipose
tissue [17], and since visceral adipose tissue exerts a larger
impact on whole-body metabolism than subcutaneous fat
[15, 16] we focused our immunological analyses on the for-
mer. To investigate whether inflammation and macrophage
recruitment were altered between diets and genotypes, we
measured gene expression levels of Tnf𝛼, Il-6, Mcp-1, Cd68,
and Socs3 in eWATof Ffar4HET andKOmice (Figure 5).The
proinflammatory cytokine, Tnf𝛼, was significantly increased
in 𝜔6-PUFA fed mice compared to LFD reference mice
(Figures 5(a) and 5(f)). Interestingly, the expression levels of
Il-6 were substantially reduced in 𝜔3-PUFA fed mice of both
genotypes compared to their LFD fed counterparts (Figures
5(b) and 5(g)), suggesting a FFAR4 independent mechanism
for at least some anti-inflammatory effects of 𝜔3-PUFAs.
Obesity-associated low-grade inflammation is characterized
by increased macrophage accumulation in adipose tissue [5]
and increased expression ofMcp-1 is hypothesized to account
for this increase [4]. While others have found that 𝜔3-
PUFA supplementation suppressed the expression of Mcp-
1 in adipose tissue of Ffar4 WT mice but not Ffar4 KO
mice [17], we found no differences in Mcp-1 expression
between genotypes (2-way ANOVA 𝑝 = 0.8274). Further,
the expression of Mcp-1 was indistinguishable between 𝜔3-
PUFA fed mice and LFD reference mice, whereas 𝜔6-PUFA
fed mice had an augmented Mcp-1 expression (Figures 5(c)
and 5(h)) concomitantwith increased expression of the global
macrophage marker, Cd68 (Figures 5(d) and 5(i)), indicating
an augmented infiltration of macrophages in adipose tissue
of 𝜔6-PUFA fed mice. Lastly, as a marker of general tissue
inflammation, we analyzed the expression levels of Socs3.
Strikingly, the finding mirrored the expression levels of Il-6
with a selective reduction of Socs3 expression in 𝜔3-PUFA
fedmice (Figures 5(e) and 5(j)) independent of FFAR4 status,
further supporting the notion of diminished inflammation
and implying that FFAR4-independent pathways may confer
beneficial effects of 𝜔3-PUFAs.
4. Discussion
The potential of fish oil to protect against cardiovascular
diseases is well-established [33]. In recent years, however,
there has been an increasing interest in the ability of fish
oil to relieve other lifestyle diseases such as obesity and
type 2 diabetes. Although human studies are inconclusive,
the antiobesogenic potential of fish oil in rodents is well-
documented [34, 35]. Still, the molecular mechanisms by
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Figure 3: Intake of a high fat 𝜔3-PUFA diet alleviates hepatic lipid accumulation in Ffar4 HET and KO mice. Mice were euthanized in
nonfasting state 36 weeks after diet initiation. Gene expression levels were analyzed by RT-qPCR and lipid levels were evaluated by thin-layer
chromatography. ((a)–(f)) Heterozygotes. ((g)–(l)) Knockouts. ((a) and (g)) mRNA level of Scd1, 𝑛 = 5–8. ((b) and (h)) mRNA level of Fas,
𝑛 = 6–8. ((c) and (i)) mRNA level of Acox1 𝑛 = 6–8. ((d) and (j)) mRNA level ofMcad, 𝑛 = 6–8. ((e) and (k)) mRNA level of Ppar𝛾2, 𝑛 = 6–8.
((f) and (l)) Triacylglycerol content, 𝑛 = 6–8. Data are presented as means ± SEM. Both HFDs have been compared to the LFD. All data
have been Ln-transformed and 1-way ANOVA with Bonferroni correction was performed. Only statistical significant differences are shown.
∗∗𝑝 < 0.01, ∗∗∗𝑝 < 0.001, and ∗∗∗∗𝑝 < 0.0001.
which 𝜔3-PUFAs mediate their actions are intensely debated
[17, 28, 36–41]. Several mechanisms have been proposed to
explain the beneficial effects of 𝜔3-PUFA supplementation,
comprising increased fatty acid oxidation [28, 38] and anti-
inflammatory actions [17, 40, 42], alleviating insulin resis-
tance andmetabolic syndrome [43]. On this note, FFAR4was
recently reported to be responsible for the anti-inflammatory
and insulin-sensitizing effects of 𝜔3-PUFAs [17].This finding
led us to investigate whether fish oil on a background of high
fat, high sucrose diet would improvemetabolic parameters in
Ffar4 KO mice to the same extent as observed in WT mice.
We compared the results to LFD reference group and further
employed an obesogenic HFD control where the fat source
was based on soy oil, rich in 𝜔6-PUFAs. Importantly, the
𝜔6-PUFA in soy oil is linoleic acid (LA), which parallels 𝜔3-
PUFAs in the ability to agonize FFAR4 [44].
We found that the decreased liver weights of 𝜔3-PUFA
fed mice were paralleled by decreased expressions of genes
encoding the lipogenic enzymes, Fas and Scd1, possibly due
to suppression of processing or activity of SREBP1c [37, 45],
and an increased expression of genes involved in fatty acid
oxidation, Acox1 and Mcad. Moreover, expression of Nrf1,
a transcription factor protecting against hepatic steatosis
[46], was selectively decreased in 𝜔6-PUFA fed mice, while
Ppar𝛾2 was increased; the latter is possibly reflecting a
requirement for increased fat storage [31], which was further
supported by increased TAG accumulation in the livers of
these mice. The protection against weight gain and liver
lipogenesis and adipogenesis in 𝜔3-PUFA fed mice was
associated with improved insulin sensitivity as determined
by an ITT. The improved insulin sensitivity was further
supported by lowered fasting plasma insulin and augmented
plasma adiponectin. Importantly, both the beneficial effects
of 𝜔3-PUFA feeding and the detrimental effects of 𝜔6-
PUFA feeding were independent of genotype. These findings
reflect a recent study focusing on energy metabolism and
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Figure 4: Intake of a high fat 𝜔3-PUFA diet alleviates hepatic steatosis in Ffar4HET and KOmice. Mice were euthanized in nonfasting state
36 weeks after diet initiation. Gene expression levels were analyzed by RT-qPCR and protein levels were evaluated by western blot analysis.
((a)–(e)) Heterozygotes. ((f)–(j)) Knockouts. ((a) and (f)) mRNA level of Il-6, 𝑛 = 5–7. ((b) and (g)) Protein level of NF𝜅B, 𝑛 = 6–8. ((c) and
(h)) mRNA level of Irs2, 𝑛 = 6–8. ((d) and (i)) mRNA level ofNrf1, 𝑛 = 6–8. ((e) and (j)) mRNA level ofMcp-1, 𝑛 = 6–8. Data are presented as
means± SEM. BothHFDs have been compared to the LFD. All data have been Ln-transformed and 1-wayANOVAwith Bonferroni correction
was performed. Only statistical significant differences are shown. ∗𝑝 < 0.05, ∗∗𝑝 < 0.01, and ∗∗∗𝑝 < 0.001.
energy expenditure which questioned the necessity of FFAR4
signaling in fish oil-mediated health benefits [23]. Yet, the
anti-inflammatory action of FFAR4-mediated signaling, as
reported by Oh et al. [17], has so far remained unchallenged.
Accordingly, we investigated the inflammatory status of liver
and visceral fat (eWAT), where a potential anti-inflammatory
effect may exert a major impact on whole-body metabolism.
Surprisingly, we found decreased expression of inflammatory
genes and proteins in 𝜔3-PUFA fed mice irrespective of
genotypes suggesting that FFAR4 is dispensable for the
immunometabolic effects of 𝜔3-PUFAs. This is in sharp
contrast to the findings of Oh et al., who found decreased
expression of Il-6 and Mcp-1 solely in WT mice, but not
in Ffar4 KO mice, fed a 𝜔3-PUFA enriched HFD [17]. The
different outcomes of the studies performed by Oh et al.
[17] and those reported here may relate to subtle differences
in the experimental setup. Both studies were performed on
mice of mixed 129SVE and C57BL/6J backgrounds, but it
is unclear to what extent the mice of the Oh et al. study
had been backcrossed to the C57BL/6J background [17]. This
could have a vast impact on the immunological outcomes of
these studies, since C57BL/6J and 129SVEmice have different
inflammatory responses [47]. Furthermore, our HET and
KO mice were cocaged throughout the study. It has been
shown that the microbiota in some instances might exert
a larger impact on phenotype compared to genotype [48].
Accordingly, it is indeed possible that the effect of cocaging,
hence exposing Ffar4KOmice tomicrobiota fromHETmice,
had masked the effect of Ffar4 ablation.
Collectively, our findings demonstrate that 𝜔3-PUFAs
may exert positive effects independently of FFAR4 or at least
that the effect of FFAR4 is minor in the setting of a high fat
fish oil-based diet. This is not to question the well-described
anti-inflammatory and insulin-enhancing potential of FFAR4
[17, 22] but merely an indication of the fact that there might
be a certain level of redundancy of the said receptor and
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Figure 5: Inflammatory status of eWAT is indistinguishable between Ffar4 HET and KO mice. Mice were euthanized in nonfasting state
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that 𝜔3-PUFAs may have multiple undiscovered receptors
through which they exert their beneficial actions. Indeed,
𝜔3-PUFAs impact a myriad of metabolic processes, and
the extent to which FFAR4 signaling is involved remains
to be elucidated. Besides increasing adiponectin secretion
[36], reported here to be independent of FFAR4, EPA
and DHA serve as precursors for bioactive lipid media-
tors such as eicosanoids/docosanoids [49], resolvins [40],
maresins [50], and protectins [51]. These compounds have
anti-inflammatory effects and may potentially curb HFD-
mediated low-grade inflammation, thereby relieving insulin
resistance. Moreover, EPA and DHA-derived prostanoids are
considered less proinflammatory than those derived from
arachidonic acid (AA) [52]. Competition between𝜔3-PUFAs
and AA for incorporation into phospholipids furthermore
reduces substrate availability for synthesis of a number of
oxylipins [53] as well as the two major endocannabinoids
[54, 55]. The importance of such lipid mediators in relation
to FFAR4-dependent signaling remains to be established. It
has been shown that the beneficial effects on hepatic steatosis
and adipose tissue insulin sensitivity by supplementing ob/ob
mice with𝜔3-PUFAswere due to increased levels of protectin
D1 and resolvin D1 [40]. These mediators have not been
investigated in the present study, and future studies are
needed to explore to what extent such lipid mediators con-
tribute to the beneficial effects associated with fish oil intake.
Additional candidates involved in 𝜔3-PUFA signaling may
comprise other G-protein coupled receptors, for example,
FFAR1 and GPR119. Indeed, FFAR1 has been shown to partly
mediate the anti-inflammatory effects of DHA by inhibition
of inflammasome activation, where only Ffar4/Ffar1 double
KO abrogated this effect [56]. Hence, the beneficial effects of
high dose 𝜔3-PUFAs may also in part be mediated by FFAR1.
Moreover, DHA, EPA, and their derivatives can activate
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PPARs, which collectively have been found to be able to
inhibit inflammation through repression of NF𝜅B activation
[57]. Furthermore, adiponectin secretion has been shown to
be PPAR𝛾-dependent [36], while PPAR𝛼 activation leads to
increased fatty acid oxidation [57], thus establishing PPARs as
important mediators and possible effectors of the 𝜔3-PUFA-
mediated FFAR4 independent effects described in the present
study.
In conclusion, our data provide evidence for alternative
routes, not dependent on FFAR4, involved in mediating the
beneficial effect of𝜔3-PUFAs, and emphasize the importance
of 𝜔3-PUFAs in relation to adequate immune regulation in
curtailing the metabolic syndrome.
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